T&R Biofab KRX:246710KOSDAQ
티앤알바이오팹 · Korean news coverage and regulatory filings, organized.
In Q2 2026, T&R Biofab reported revenue of ₩9.5bn, up 45.9% year on year, and an operating loss of ₩928m. T&R Biofab (티앤알바이오팹) appeared in 11 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Nov 11 with 6 articles. The most common catalyst was tech & capacity (1). It was most often mentioned alongside 글로벌테크놀로지.
Filing signals 4 quarters of losses Screener
T&R Biofab today: up or down?
No sign-up, one tap a day. These numbers show what visitors think and are not investment advice.
Upcoming dates as filed
- Mar 31 Annual report filing deadlinein 134 days · period ending Dec 2026
Dates T&R Biofab stated in its DART filings. A conversion period opening does not mean new shares appear that day; bondholders must request conversion.
T&R Biofab quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩9.5bn | +45.9% | −₩928m margin −9.7% | −₩3.8bn |
| Q1 2026 | ₩8.7bn | +46.5% | −₩931m margin −10.7% | −₩1.7bn |
| Q4 2025 derived | ₩7.5bn | +511.9% | −₩2.3bn margin −30.5% | −₩16.6bn |
| Q3 2025 | ₩7.0bn | +534.1% | −₩1.3bn margin −18.2% | −₩5.7bn |
| Q2 2025 | ₩6.5bn | +380.4% | −₩1.9bn margin −29.3% | −₩4.3bn |
| Q1 2025 | ₩6.0bn | +401.5% | −₩3.6bn margin −60.1% | −₩5.4bn |
| Q4 2024 derived | ₩1.2bn | – | −₩2.6bn margin −212.6% | ₩5.8bn |
| Q3 2024 | ₩1.1bn | +15.1% | −₩3.1bn margin −279.2% | −₩4.8bn |
T&R Biofab ranks #2054 of 2,582 Korean listed companies by Q2 2026 operating profit. Q2 2026 Korean earnings rankings →
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
T&R Biofab top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest T&R Biofab news Korean headlines
-
T&R Biofab participates in Medica 2026...expanding medical device distribution channels
1 more on this story · 1 outlets
-
T&R Biofab acquires patent for artificial skin technology replicating human skin texture
2 more on this story · 2 outlets
-
T&R BioPharma reports third-quarter cumulative sales of 27.2 billion won, up 39.7% year-over-year
5 more on this story · 4 outlets
- T&R BioPharma achieves third-quarter cumulative sales of 27.2 billion won이데일리 · Oct 19 14:13
- T&R BioPharma achieves third-quarter cumulative sales of 27.2 billion won이데일리증권 · Oct 19 14:13
- T&R BioPharma achieves third-quarter cumulative sales of 27.2 billion won이데일리 · Oct 19 14:15
- T&R BioPharma posts third-quarter cumulative sales of 27.2 billion won, up 39.7% year-over-year핀포인트뉴스 · Oct 19 14:19
- T&R BioPharma reports third-quarter cumulative sales of 27.2 billion won, up 39.7% year-over-year현대경제신문 · Oct 19 14:27
-
T&R BioPharma posts third-quarter cumulative sales of 27.2 billion won, medical devices and subsidiary grow together
1 more on this story · 1 outlets
- T&R BioPharma's third-quarter cumulative sales up 39.7%, medical devices growth메디파나뉴스 · Oct 19 11:07